Intravenous Etidronate in the Management of Malignant Hypercalcemia

Elisabeth Ryzen, Raymond R. Martodam*, Mark Troxell, Al Benson, Alexander Paterson, Kirk Shepard, Richard Hicks

*Corresponding author for this work

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

• The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

Original languageEnglish (US)
Pages (from-to)449-452
Number of pages4
JournalArchives of Internal Medicine
Volume145
Issue number3
DOIs
StatePublished - Jan 1 1985

Fingerprint

Etidronic Acid
Hypercalcemia
Therapeutics
Serum
Multiple Myeloma
Non-Small Cell Lung Carcinoma
Reaction Time
Creatinine
Neoplasms
Reference Values
Breast Neoplasms
Calcium

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ryzen, E., Martodam, R. R., Troxell, M., Benson, A., Paterson, A., Shepard, K., & Hicks, R. (1985). Intravenous Etidronate in the Management of Malignant Hypercalcemia. Archives of Internal Medicine, 145(3), 449-452. https://doi.org/10.1001/archinte.1985.00360030089018
Ryzen, Elisabeth ; Martodam, Raymond R. ; Troxell, Mark ; Benson, Al ; Paterson, Alexander ; Shepard, Kirk ; Hicks, Richard. / Intravenous Etidronate in the Management of Malignant Hypercalcemia. In: Archives of Internal Medicine. 1985 ; Vol. 145, No. 3. pp. 449-452.
@article{694b356f402b4012a8faed68d2d3959b,
title = "Intravenous Etidronate in the Management of Malignant Hypercalcemia",
abstract = "• The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73{\%}) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.",
author = "Elisabeth Ryzen and Martodam, {Raymond R.} and Mark Troxell and Al Benson and Alexander Paterson and Kirk Shepard and Richard Hicks",
year = "1985",
month = "1",
day = "1",
doi = "10.1001/archinte.1985.00360030089018",
language = "English (US)",
volume = "145",
pages = "449--452",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

Ryzen, E, Martodam, RR, Troxell, M, Benson, A, Paterson, A, Shepard, K & Hicks, R 1985, 'Intravenous Etidronate in the Management of Malignant Hypercalcemia', Archives of Internal Medicine, vol. 145, no. 3, pp. 449-452. https://doi.org/10.1001/archinte.1985.00360030089018

Intravenous Etidronate in the Management of Malignant Hypercalcemia. / Ryzen, Elisabeth; Martodam, Raymond R.; Troxell, Mark; Benson, Al; Paterson, Alexander; Shepard, Kirk; Hicks, Richard.

In: Archives of Internal Medicine, Vol. 145, No. 3, 01.01.1985, p. 449-452.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravenous Etidronate in the Management of Malignant Hypercalcemia

AU - Ryzen, Elisabeth

AU - Martodam, Raymond R.

AU - Troxell, Mark

AU - Benson, Al

AU - Paterson, Alexander

AU - Shepard, Kirk

AU - Hicks, Richard

PY - 1985/1/1

Y1 - 1985/1/1

N2 - • The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

AB - • The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

UR - http://www.scopus.com/inward/record.url?scp=84941817796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941817796&partnerID=8YFLogxK

U2 - 10.1001/archinte.1985.00360030089018

DO - 10.1001/archinte.1985.00360030089018

M3 - Article

VL - 145

SP - 449

EP - 452

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -